These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31023843)

  • 1. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of the P2X
    Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefapixant in two randomised dose-escalation studies in chronic cough.
    Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery and development of gefapixant as a novel antitussive therapy.
    Matera MG; Rogliani P; Page CP; Calzetta L; Cazzola M
    Expert Opin Drug Discov; 2024 Oct; 19(10):1159-1172. PubMed ID: 39138872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
    Dicpinigaitis PV; McGarvey LP; Canning BJ
    Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
    Kum E; Patel M; Diab N; Wahab M; Zeraatkar D; Chu DK; O'Byrne PM; Guyatt GH; Satia I
    JAMA; 2023 Oct; 330(14):1359-1369. PubMed ID: 37694849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
    Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
    Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.
    Hilton EC; Baverel PG; Woodcock A; Van Der Graaf PH; Smith JA
    J Allergy Clin Immunol; 2013 Oct; 132(4):847-55.e1-5. PubMed ID: 23777849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cough reduction using capsaicin.
    Ternesten-Hasséus E; Johansson EL; Millqvist E
    Respir Med; 2015 Jan; 109(1):27-37. PubMed ID: 25468411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
    Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
    Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.